Geode Capital Management’s Co-Diagnostics CODX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-14,972
Closed -$81.2K 4538
2025
Q4
$81.2K Buy
14,972
+4,306
+40% +$46.9K ﹤0.01% 4142
2025
Q3
$110K Hold
10,666
﹤0.01% 4107
2025
Q2
$89.7K Sell
10,666
-740
-6% -$6.92K ﹤0.01% 4090
2025
Q1
$106K Sell
11,406
-111
-1% -$2.12K ﹤0.01% 4016
2024
Q4
$259K Buy
11,517
+808
+8% +$25.5K ﹤0.01% 3813
2024
Q3
$402K Buy
10,709
+130
+1% +$4.99K ﹤0.01% 3678
2024
Q2
$397K Buy
10,579
+765
+8% +$27.8K ﹤0.01% 3654
2024
Q1
$330K Hold
9,814
﹤0.01% 3766
2023
Q4
$392K Hold
9,814
﹤0.01% 3705
2023
Q3
$312K Sell
9,814
-258
-3% -$9.75K ﹤0.01% 3798
2023
Q2
$335K Sell
10,072
-578
-5% -$22.1K ﹤0.01% 3803
2023
Q1
$473K Hold
10,650
﹤0.01% 3667
2022
Q4
$805K Buy
10,650
+496
+5% +$46.4K ﹤0.01% 3456
2022
Q3
$977K Buy
10,154
+114
+1% +$15.9K ﹤0.01% 3402
2022
Q2
$1.69M Buy
10,040
+1,226
+14% +$186K ﹤0.01% 3173
2022
Q1
$1.63M Buy
8,814
+269
+3% +$55.7K ﹤0.01% 3363
2021
Q4
$2.29M Sell
8,545
-5
-0.1% -$1.31K ﹤0.01% 3301
2021
Q3
$2.5M Buy
8,550
+610
+8% +$178K ﹤0.01% 3258
2021
Q2
$1.97M Sell
7,940
-6,577
-45% -$1.69M ﹤0.01% 3272
2021
Q1
$4.15M Buy
14,517
+1,480
+11% +$591K ﹤0.01% 2880
2020
Q4
$3.64M Buy
13,037
+1,021
+8% +$378K ﹤0.01% 2765
2020
Q3
$4.9M Buy
12,016
+1,001
+9% +$514K ﹤0.01% 2409
2020
Q2
$6.39M Buy
11,015
+6,972
+172% +$3.18M ﹤0.01% 2199
2020
Q1
$924K Buy
4,043
+2,433
+151% +$422K ﹤0.01% 3054
2019
Q4
$43K Hold
1,610
﹤0.01% 4105
2019
Q3
$49K Hold
1,610
﹤0.01% 4063
2019
Q2
$39K Hold
1,610
﹤0.01% 4103
2019
Q1
$51K Hold
1,610
﹤0.01% 4018
2018
Q4
$70K Hold
1,610
﹤0.01% 3927
2018
Q3
$126K Hold
1,610
﹤0.01% 3882
2018
Q2
$187K Buy
+1,610
New +$131K ﹤0.01% 3734

Other funds holding CODX

Geode Capital Management's CODX Position: Q1 2026 in Review

Geode Capital Management sold out of Co-Diagnostics (CODX) in Q1 2026, closing a stake of 14,972 shares — an estimated $81.2K sold.

Geode Capital Management first reported a position in CODX in Q2 2018 and held it in 31 quarters. The position peaked at $6.39M in Q2 2020. 14 funds tracked by Wall St. Rank hold CODX as of Q1 2026.

  • Geode Capital Management reported no remaining Co-Diagnostics position as of Q1 2026 after selling out during the quarter.
  • Geode Capital Management sold 14,972 Co-Diagnostics shares in Q1 2026, an estimated $81.2K.
  • Geode Capital Management first reported a position in Co-Diagnostics in Q2 2018 and held it in 31 quarters.
  • Geode Capital Management's Co-Diagnostics position peaked at $6.39M in Q2 2020.
  • 14 funds tracked by Wall St. Rank held Co-Diagnostics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.